Metal-Organic Frameworks (MOFs) materials are hybrid nanostructures produced by the interfacial bonding between the self assembled metal ions and organic linker moieties, offering a novel design strategy and tailor-made features possessing various applications in the field of catalysis, a molecular dispensation of drugs, photocatalytic dye degradation, sensors and energy storage. MOFs remain a most valuable candidate in the catalysis area and dye degradation because of their tunable nature, surface-volume ratio, facile dispersibility, unique morphology and high porous nature, thereby benefiting the ionic diffusion in the interfacial layer of the active sites. Over the past decades, zirconium-based MOFs are used progressively as porous material that persists as a potential nominee due to their greater capacities and synergism with the metal ions and composites as precursors [1]. Pyrimidines and its derivatives are gaining importance in medicinal and organic chemistry [2]. They have displayed broad spectrum of pharmacological and biological activities, such as antibacterial, antidepressant, antihyperglycemic, anti-inflammatory, and antitumor [3]. In particular, condensed pyrimidines are known for various biological activities, for example, pyrido[2,3-d]pyrimidine compounds are useful for treatment of a wide variety of stress-related illnesses, such as depression, Alzheimer's disease, gastrointestinal disease, anorexia nervosa, hemorrhaged stress, drug and alcohol withdrawal symptoms, drug addition and infertility [4]. Herein, we have introduced a suitable method for the synthesis of pyrido[2,3-d]pyrimidine compounds using the prepared catalyst zirconium-based metal organic framework at 100 ̊C under solvent-free conditions.
